Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Shortened Dual Antiplatelet Therapy
Author(s): Kevin S Tang , Shoujit Banerjee , George Tang , et al Added: 2 years ago

Anticoagulation

Intervention
TCT 23: AGENT IDE
Author(s): Robert Yeh Added: 2 years ago
TCT 23 - In this short online interview, we are joined by Dr Robert Yeh (Beth Israel Deaconess Medical Center, US) to discuss the findings of the AGENT IDE trial (NCT04647253), sponsored by Boston Scientific. AGENT IDE is a prospective, 2:1 randomized multicenter trial that aimed to compare the AGENT paclitaxel-coated balloon to plain-old balloon angioplasty (POBA) with a commercially available… View more

Intervention
CRT 25: AGENT IDE: 2Y Outcomes
Author(s): Jeffrey W Moses Added: 11 months ago
CRT 25 - Safety and effectiveness outcomes of the Agent drug-coated balloon (DCB) for the treatment of in-stent restenosis show a major reduction in target lesion failure, including cardiac death, myocardial infarction and target lesion revascularization, compared to balloon angioplasty. The Agent DCB also caused a significant reduction in all target lesion events in comparison with the control… View more

Intervention

Vascular Disease and Surgery
SCAI 25: Insights from the TRITAVI Registry
Author(s): Francesco Pelliccia Added: 9 months ago
SCAI 2025 - Insights from antiplatelet therapy after transcatheter aortic valve replacement (TAVR) show patients who received single antiplatelet treatment had significantly lower rates of overall six-month mortality, CV death and non-CV death compared to those treated with double antiplatelet treatment.Dr Francesco Pelliccia (Sapienza University of Rome, Rome, IT) joins us to discuss insights… View more

Anticoagulation

Intervention
Johanne Silvain
Job title: Prof. Johanne Silvain is professor of medicine at the Pierre and Marie Curie University in Paris, France.
He is an interventional cardiologist, with experience in coronary angioplasty and OTC, and is Director of the Coronary Intensive Care Unit.He is licensed at the University of Medicine of Paris (UPMC) and is the author of over 100 publications in prestigious authoritative journals.The research interests of Dr. Silvain fall within the field of thrombosis (composition of thrombi) and antithrombotic… View more
Left Atrial Appendage Occlusion: BCIS and BHRS Position Statement
Author(s): Tim R Betts , Patrick A Calvert , Lee N Graham , et al Added: 1 year ago

Electrophysiology & Arrhythmia

Intervention
PFO Closure: BCIS Position Statement
Author(s): Mark Turner , Suneil Aggarwal , Michael J Mullen , et al Added: 12 months ago

Intervention
View from the Thoraxcenter: TCT 23 Late-breaking Science Wrap Up
Author(s): Nicolas M Van Mieghem , Joost Daemen Added: 2 years ago
What are the top late-breaking trials from #TCT2023? TCT 2023 — Join interventional cardiologists, Prof Nicolas Van Mieghem and Dr Joost Daemen from the Thoraxcenter as they unpack the most impactful late-breaking clinical trials and science data from this year's Transcatheter Cardiovascular Therapeutics Conference. Dive into this practical and engaging discussion and learn more about the… View more

Intervention
View from the Thoraxcenter: TCT 23 Late-breaking Science Preview
Author(s): Joost Daemen , Nicolas M Van Mieghem Added: 2 years ago
What's hot at TCT 2023? In this episode of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, NL) preview the late-breaking data presented at TCT 2023. With their dynamic analysis, these anticipated trials are placed in context, highlighting the real-world implications tied to the data releases. Top trials covered: 00:31 - 02:12: PARTNER 3 Low… View more

Intervention
Individualising Antithrombotic Strategies for ACS and CCS
Author(s): Robert F Storey Added: 1 year ago

Anticoagulation

Intervention